Dongcheng Pharmaceutical Adds New Radiopharmaceutical Production Center in Jinzhong, Shanxi

Recently, Shanxi Andike, a subsidiary of Dongcheng Andike, which is a wholly-owned subsidiary of Dongcheng Pharmaceutical, received the "Radiopharmaceutical Production License" issued by the Shanxi Provincial Drug Administration. This marks that the Jinzhong Radiopharmaceutical Production Center in Shanxi has met the requirements for commissioning, adding a new facility to Dongcheng Pharmaceutical's radiopharmaceutical production network. As one of China's leading nuclear medicine companies, the group adheres to a layout strategy of "networked short half-life and base-based long half-life" production, and has established a domestically leading radiopharmaceutical production and distribution network. To date, the group has put 33 radiopharmaceutical production centers into operation.

As a "heparin expert and radiopharmaceutical pioneer," Dongcheng Pharmaceutical will continue to deepen its presence in the nuclear medicine field, striving to build a comprehensive Dongcheng nuclear medicine ecosystem. Leveraging its strengths in innovative R&D, product pipelines, and production and distribution networks, the company is committed to continuously meeting clinical needs and benefiting patients.